Drug Delivery: Surveying the Global Competitive Landscape26 Jan 2011 • by Natalie Aster
“In June 2010, Eurand reported additional data from a post hoc analysis of a Phase III trial with Zenpep (pancrelipase) delayedrelease capsules, an FDA-approved pancreatic enzyme product (PEP) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions. The study results demonstrated that patients with EPI due to CF can be transferred effectively from their previous PEPs to Zenpep. Results from a post hoc analysis of a Phase III, randomised, double-blind, placebo-controlled crossover study in 34 patients with EPI due to CF demonstrated that patients experienced a significant and rapid symptom improvement when switched from their previous PEP to Zenpep at a comparable daily dose.”
The new, richly-detailed report “Drug Delivery: Surveying the Global Competitive Landscape” by Espicom Business Intelligence provides the most comprehensive review of the sector and examines the competitive drug delivery landscape with analysis of 114 key companies. The company landscape is always changing: some have been bought by the big boys and aspiring developers, whilst others have just run out of money and gone to the wall. Slowly but surely the private equity groups - most of whom have been in relative hibernation for the past couple of years - are gradually returning to the fold and supporting financing rounds.
The report provides with key data for each featured company:
- Company Overview & Technology Focus;
- Key Personnel;
- Competition & Competing Products;
- Key Milestones;
- R&D & Research Strategy;
- Key Agreements & Alliances;
- Financial Data (where available);
- Comprehensive Contact Details.
Published: January 2011
Price: USD 1,040
Report Sample Abstract:
Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products using its drug-delivery technologies.
Eurand’s principal operating offices are in Milan, Italy with commercial offices in New York, USA. The company has R&D and manufacturing facilities throughout the world, including sites in Milan and Trieste, Italy; Dayton, OH; and Paris, France.
- Eurand’s Board of Directors accepted the terms of an all-cash offer for the company from Axcan Pharma which valued Euran at US$583 million. The deal is expected to be completed sometime in the first quarter of 2011, subject to conditions.
- November 2009 - Eurand marked the US commercial release of Zenpep (pancrelipase) delayed-release capsules, a pancreatic enzyme product indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. The product secured FDA approval in August 2009.
- May 2009 - The FDA approved EUR-1048, which is marketed as GlaxoSmithKline’s (GSK) Lamictal orally disintegrating tablet (lamotrigine). Co-developed by Eurand and GSK, Lamictal ODT uses Eurand’s AdvaTab ODT and Microcaps tastemasking technologies to provide Lamictal in a ‘pleasant-tasting’ tablet that disintegrates on the tongue and that may be taken with or without liquid.
- June 2008 - Eurand received an approvable letter from the FDA for its NDA for EUR-1008 (pancrealipase capsules) for the treatment of exocrine pancreatic insufficiency. The NDA was accepted for review by the FDA in February 2008.
Eurand has four technology platforms:
- Bioavailability Enhancement;
- Customised Drug Release;
- Taste-Masking and Orally Disintegrating Tablets;
- Drug Conjugation.
More information can be found in the report “Drug Delivery: Surveying the Global Competitive Landscape” by Espicom Business Intelligence.
To order the report or ask for sample pages contact email@example.com